TAS-116, a Novel, Orally Bioavailable HSP90a/β Selective Inhibitor Demonstrates Highly Potent Antitumor Activity in Preclinical Models with a Favorable PK Profile

被引：3
|
作者：
Ohkubo, S. [1 ]
Muraoka, H. [1 ]
Hashimoto, A. [1 ]
Ito, S. [1 ]
Ito, K. [1 ]
Shibata, Y. [1 ]
Kanoh, A. [1 ]
Kitade, M. [1 ]
Yonekura, K. [1 ]
Utsugi, T. [1 ]
机构：
[1] Taiho Pharmaceut Co LTD, Tsukuba Res Ctr, Tsukuba, Ibaraki, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)72089-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
291
引用
收藏
页码：89 / 89
页数：1
相关论文
共 50 条
  • [21] PLX4032, a selective B-RafV600E inhibitor demonstrates potent antitumor activity in preclinical melanoma models
    Su, Fei
    Yang, Hong
    Higgins, Brian
    Kolinsky, Kenneth
    Lee, Richard
    Packman, Kathryn
    Schostack, Kathleen
    Heimbrook, David
    Bollag, Gideon
    CANCER RESEARCH, 2009, 69
  • [22] TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
    Irie, Hiroki
    Ito, Kimihiro
    Fujioka, Yayoi
    Oguchi, Kei
    Fujioka, Akio
    Hashimoto, Akihiro
    Ohsawa, Hirokazu
    Tanaka, Kenji
    Funabashi, Kaoru
    Araki, Hikari
    Kawai, Yuichi
    Shimamura, Tadashi
    Wadhwa, Renu
    Ohkubo, Shuichi
    Matsuo, Kenichi
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (04) : 733 - 742
  • [23] INCB161734: A novel, potent, and orally bioavailable KRAS G12D selective inhibitor demonstrates antitumor activity in KRAS G12D mutant tumors
    Farren, Matthew R.
    Roman, Valerie
    Gallion, Alexandra
    Allali-Hassani, Abdellah
    Sokolsky, Alexander
    Kong, Weixi
    Smith, Amanda
    Wang, Hui
    Correa, Gina
    Deller, Marc
    Epling, Leslie B.
    Procak, Jessica
    Zhang, Guofeng
    Pecko, Katherine
    Kennedy, Keith
    Boer, Jason
    Kurzeja-Lipinski, Kerri
    Covington, Maryanne
    Chen, Kwang-Jong
    Wallower, Renee
    Rocha, Jennifer
    Pan, Rina
    Perry, Anthony
    Yuska, Brad
    Wang, Xiaozhao
    Macarron, Ricardo
    Kim, Sunkyu
    CANCER RESEARCH, 2024, 84 (06)
  • [24] CH4987655 (RO4987655), a selective orally bioavailable MEK inhibitor, shows highly potent and broad antitumor activity as a monotherapy and in combination with other antitumor agents
    Aida, Satoshi
    Yoshimura, Yasushi
    Ishii, Nobuya
    Sakamoto, Hiroshi
    Isshiki, Yoshiaki
    Ishikawa, Yuji
    Miwa, Masanori
    Shimma, Nobuo
    Okabe, Hisafumi
    Aoki, Yuko
    CANCER RESEARCH, 2009, 69
  • [25] 143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models
    Xu, Lan-song
    Zheng, Su-xin
    Mei, Liang-he
    Yang, Ke-xin
    Wang, Ya-fang
    Zhou, Qiang
    Kong, Xiang-tai
    Zheng, Ming-yue
    Jiang, Hua-liang
    Xie, Cheng-ying
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (07) : 1475 - 1486
  • [26] 143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models
    Lan-song Xu
    Su-xin Zheng
    Liang-he Mei
    Ke-xin Yang
    Ya-fang Wang
    Qiang Zhou
    Xiang-tai Kong
    Ming-yue Zheng
    Hua-liang Jiang
    Cheng-ying Xie
    Acta Pharmacologica Sinica, 2023, 44 : 1475 - 1486
  • [27] NVP-BEP795 and NVP-BEP800: Novel, fragment derived orally bioavailable small molecule Hsp90 inhibitors with potent antitumor activity
    Massey, Andrew
    Brough, Paul
    Jensen, Michael
    Ruetz, Stephan
    Schoepfer, Joseph
    Workman, Paul
    Garcia-Echeverria, Carlos
    Drysdale, Martin
    CANCER RESEARCH, 2009, 69
  • [28] CX-5461, a novel, orally bioavailable selective small molecule inhibitor of RNA polymerase I transcription, induces autophagy and shows potent antitumor activity
    Drygin, D.
    Lin, A.
    Haddach, M.
    Ho, C.
    Bliesath, J.
    Proffitt, C.
    Schwaebe, M. T. K.
    Rice, W. A. K.
    Anderes, K. L.
    EJC SUPPLEMENTS, 2008, 6 (12): : 108 - 108
  • [29] A novel small-molecule CBP/p300 HAT domain inhibitor demonstrates potent in vivo activity and a favorable safety profile in preclinical species
    Hearn, K.
    Ahn, M.
    Bevan, L.
    Chessari, G.
    Clark, M.
    Cons, B.
    Espana-agusti, J.
    Ferro, K.
    Howard, A.
    Lyons, J.
    Martins, V.
    Morgillo, C.
    Palmer, N.
    Rapti, M.
    Shah, A.
    Smyth, T.
    Unbekandt, M.
    Varshney, D.
    Hamlett, C.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S18 - S18
  • [30] CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers
    Cheng, Mangeng
    Quail, Matthew R.
    Gingrich, Diane E.
    Ott, Gregory R.
    Lu, Lihui
    Wan, Weihua
    Albom, Mark S.
    Angeles, Thelma S.
    Aimone, Lisa D.
    Cristofani, Flavio
    Machiorlatti, Rodolfo
    Abele, Cristina
    Ator, Mark A.
    Dorsey, Bruce D.
    Inghirami, Giorgio
    Ruggeri, Bruce A.
    MOLECULAR CANCER THERAPEUTICS, 2012, 11 (03) : 670 - 679
12345